{"product_id":"pacira-soar-analysis","title":"Pacira SOAR Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Pacira SOAR Analysis gives you a clear, company-specific breakdown of strengths, opportunities, aspirations, and results for research, strategy, or investing. The page already shows a real preview of the actual content, so you can review the format and substance before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Presence with Flagship Asset EXPAREL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira’s biggest strength is EXPAREL, the only long-acting local anesthetic approved for a broad set of surgical uses, giving the company a rare moat in non-opioid pain care. By early 2026, EXPAREL had treated more than 15 million patients, which supports strong brand trust in postsurgical pain control. That scale helps Pacira win hospital contracts and stay embedded in orthopedics, where opioid-sparing care is a high priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Intellectual Property and Technical Barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira’s DepoFoam platform is a real moat: it uses specialized 200-liter scale manufacturing that generic rivals cannot easily copy. Even after multiple patent challenges, Pacira still controls the supply chain and its unique liposomal formulation, which helps keep product quality consistent. That technical depth raises entry costs and makes exact-price, exact-profile competition hard to build.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Specialized Sales Force and Institutional Relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira’s specialized sales force is built for hospitals and ASCs, where buying decisions are clinical and sticky. By early 2026, it had relationships with key opinion leaders in more than 4,000 surgical centers across the U.S., helping place its products into care protocols and support repeat use.\u003c\/p\u003e\n\u003cp\u003eThis field-led model gives Pacira an edge over generic alternatives because surgeons and staff already know the products, the data, and the support team. In 2025, that commercial reach helped drive company revenue to about $700 million, showing how strong institution-level ties can turn into sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Product Pipeline and Technological Synergy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePacira is no longer just the \"EXPAREL\" company; by adding ioveraº, it now has two complementary non-opioid technologies that can serve the full pain-care path from pre-op to post-op. That broader suite lets sales reps sell one integrated solution for nerve-related pain instead of a single product, which supports cross-selling and deeper account penetration. In 2025, this mix helps Pacira stand out in a pain market still dominated by opioid use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePositive Cash Flow and Healthy Liquidity Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePacira’s 2025 fiscal-year cash generation gave it room to fund trials and manufacturing while still ending the year with ample liquidity. That balance matters: it supports share repurchases, debt reduction, and steady R\u0026amp;D spend without stressing the balance sheet. It also gives Pacira flexibility to absorb reimbursement swings or move on acquisitions in acute pain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePacira’s Moat Runs Deep in EXPAREL, DepoFoam, and 4,000+ Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira's strengths are EXPAREL's moat, the DepoFoam platform, and a hospital sales force embedded in more than 4,000 surgical centers. Fiscal 2025 revenue was about $700 million, and EXPAREL had treated over 15 million patients by early 2026. ioveraº and strong liquidity add cross-sell power and funding flexibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$700M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical centers\u003c\/td\u003e\n\u003ctd\u003e4,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear SOAR framework for analyzing Pacira’s strategic growth potential\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nRelieves strategy clutter by giving Pacira a clear SOAR snapshot of strengths, opportunities, aspirations, and results.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMaximizing the NOPAIN Act Implementation Tailwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira Pharmaceuticals is benefiting from the full NOPAIN Act rollout in early 2025, which gives ASCs separate Medicare reimbursement for non-opioid analgesics. That removes a key price hurdle that had pushed many sites toward cheaper generic options. As of March 2026, the company says this can help it win a larger share of Medicare-eligible surgeries, with upside of about $150 million to $200 million in incremental annual revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanding Reach into the Pediatric Patient Demographic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira has a clear opening in pediatric surgery, where families and clinicians actively try to limit opioid exposure. EXPAREL’s pediatric label expansion gives it a foothold in a segment that was mostly underserved by long-acting local anesthetics. If Pacira captured just 15% of pediatric cases, it could add a multi-million-dollar lift to the Company Name addressable market.\u003c\/p\u003e\n\u003cp\u003eThe chance is bigger because pediatric pain control is a high-stakes choice, not a commodity purchase. In 2025, the move from adult-only use to younger patients helps Pacira widen adoption without building a new product from scratch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing Gene Therapy for Osteoarthritis via PCRX-201\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePCRX-201 gives Pacira a real shot to move from postsurgical pain into chronic care, with knee osteoarthritis affecting over 32 million U.S. adults. If late-stage data keeps showing relief beyond 12 months from one injection, Pacira could reach outpatient rheumatology and a much larger recurring market than the OR alone. That would also reduce reliance on its current acute-care base and widen the revenue mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Expansion into the European and Asian Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePacira BioSciences can grow beyond its U.S. base by gaining more regulatory approvals and using local distributors in Europe and Asia. In 2025, the U.S. still drove most revenue, so even modest adoption gains in the UK and key European markets could add meaningful upside as surgical volumes rise. Local partners also cut the cost of building new infrastructure while extending DepoFoam reach faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShift toward Total Knee and Hip Arthroplasty in ASCs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eU.S. care keeps shifting from inpatient hospitals to ASCs, and that fits Pacira because EXPAREL supports earlier mobilization and same-day discharge after total knee and hip replacement. With ASCs on track to handle over 60% of orthopedic surgeries by 2026, Pacira’s foothold in these high-turnover sites makes it well placed to keep winning outpatient joint cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePacira's 2025 growth catalyst: NOPAIN, pediatrics, and PCRX-201\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira’s biggest 2025 opening is the NOPAIN Act: Medicare now pays separately for non-opioid drugs in ASCs, and management has flagged $150 million to $200 million in annual upside. That should lower price resistance and speed EXPAREL uptake in high-volume outpatient surgery.\u003c\/p\u003e\n\u003cp\u003eAnother 2025 lever is pediatric use, where EXPAREL’s label expansion opens a mostly underserved market and could add multi-million-dollar revenue if adoption builds. PCRX-201 is the longer shot, with knee osteoarthritis affecting over 32 million U.S. adults.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003e2025 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNOPAIN Act\u003c\/td\u003e\n\u003ctd\u003e$150M-$200M upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKnee osteoarthritis\u003c\/td\u003e\n\u003ctd\u003e32M+ U.S. adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient surgery\u003c\/td\u003e\n\u003ctd\u003eASC growth tailwind\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003ePacira Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re viewing the actual Pacira SOAR Analysis document, not a generic sample. The preview shown here is the same file you’ll receive after purchase, with the full report unlocked immediately afterward. Expect the same professional structure, detailed insights, and ready-to-use format in the complete version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003espirations\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolving into a Full-Scale Non-Opioid Portfolio Leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira is trying to move past its single-product label and become a full non-opioid analgesia platform. Management wants at least three distinct multi-million-dollar products by 2030, which would cut dependence on EXPAREL and widen the base beyond one asset. \u003c\/p\u003e\n\u003cp\u003eThe push is backed by reinvestment in the pipeline and steady work on ioveraº and the gene therapy program. In FY2025, that means the key test is execution: turn R\u0026amp;D spend into durable second and third revenue drivers, not just line extensions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablishing the 'Universal Standard' for Post-Surgical Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira aims to make zero-opioid recovery the default for routine surgery in North America by embedding long-acting liposomal bupivacaine into residency and fellowship training. That matters because Exparel is already used in clinical practice across many surgical settings, so the next step is normalization, not invention. If Pacira can shape education at scale, its standard could become as routine as saline or sterile tools in the OR.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAchieving Best-in-Class Operational and Manufacturing Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira’s aspiration is to fully automate and modernize its 200-liter manufacturing lines so COGS falls and scale improves. By March 2026, the goal is gross margin above 75%, which would give Pacira more room to price Exparel and other products competitively while still protecting profit. That matters if payer pressure rises, because a 75%+ margin can absorb pricing caps better than a lower-margin model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBecoming a Key Player in Modern Gene Therapy Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWith PCRX-201, Pacira aims to show that localized gene therapy can work as a specialty-care business, not just a science project. Its intra-articular, or joint-space, delivery model could avoid the broad body-wide exposure and tougher safety review that often slow systemic gene therapies. If it works, Pacira could bridge pain care and biotech, which may draw a different class of institutional investor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAggressive Debt Reduction and Long-Term Capital Returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn fiscal 2025, Pacira kept its debt plan centered on retiring convertible notes as they mature through 2026, a key step toward a fortress balance sheet. If it reaches net-zero debt, the Company Name could shift cash from deleveraging to regular dividends or larger buybacks. That would support a move from a growth biotech profile to a steadier cash-return story for long-term holders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePacira Bets on Growth Beyond EXPAREL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira's FY2025 aspiration is to move beyond EXPAREL by building at least three multi-million-dollar products by 2030 and turning non-opioid pain care into a broader platform. The Company also wants gross margin above 75% and a cleaner balance sheet as convertibles mature through 2026, so cash can shift from debt paydown to growth.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesults\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYear-Over-Year Revenue Growth Crossing Historical Highs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira closed fiscal 2025 with record annual revenue above $750 million, reflecting strong volume gains after NOPAIN Act adoption. The company kept pricing firm even as competition rose, showing solid demand and disciplined execution. Eight straight quarters of revenue growth point to a commercial engine that is still gaining share and scaling well.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Expansion of the Outpatient Customer Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of early 2026, more than 55% of EXPAREL use came from ambulatory surgery centers, a record high for Pacira BioSciences, Inc. This shows a clear shift from hospital-only use to the faster-growing outpatient market. It also suggests surgeons in ASCs see enough clinical value to adopt EXPAREL when reimbursement is in place.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Regulatory Clearance for Expanded Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira’s late-2024 and 2025 label wins expanded EXPAREL use into new nerve block settings and pediatric patients, including children ages 6 to 17. The clearer labeling helped push utilization up 10% in sub-specialties such as pediatric spine surgery. That kind of adoption matters: Pacira turned R\u0026amp;D spend into approved uses that rivals cannot copy quickly. In 2025, this also supported broader clinical pull across hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable Operating Margins through Cost Containment Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEarly 2026 operating results show Pacira improved operating margin by about 300 basis points, helped by upgrades at its San Diego manufacturing site. The gains suggest automation and tighter process control are offsetting higher labor and raw-material costs. That points to stronger cost discipline as revenue grows, with overhead kept in check.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Safety Record with Millions of Procedures Completed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSince its 2012 launch, EXPAREL has accumulated post-market use across millions of doses, and Pacira reported no major safety signal or product withdrawal through 2025. That long, real-world record gives hospital buyers a clear low-risk signal, which matters when safety data can decide contracts in large systems.\u003c\/p\u003e\n\u003cp\u003eFor cautious administrators, a 13-year safety track record is a strong proof point, especially versus newer products that still lack broad surveillance data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePacira Hits Record Revenue as ASC Adoption and Margins Surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, Pacira posted record revenue above $750 million, and growth ran for eight straight quarters. EXPAREL adoption kept shifting to ambulatory surgery centers, which topped 55% of use by early 2026. The company also lifted operating margin by about 300 basis points, helped by manufacturing upgrades.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eAbove $750 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASC share\u003c\/td\u003e\n\u003ctd\u003eAbove 55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin\u003c\/td\u003e\n\u003ctd\u003e+300 bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SOAR Analysis","offers":[{"title":"Default Title","offer_id":52938574987611,"sku":"pacira-soar-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/6857\/8907\/files\/pacira-soar-analysis.webp?v=1778326099","url":"https:\/\/soar-analysis.com\/products\/pacira-soar-analysis","provider":"SOAR Analysis","version":"1.0","type":"link"}